Orchid's PDE-4 inhibitor shows early promise in European study
This article was originally published in Scrip
Orchid Chemicals & Pharmaceuticals expects to start Phase IIa studies in Europe by March with its oral phosphodiesterase-4 (PDE-4) inhibitor OCID 2987 for inflammatory disorders including chronic obstructive pulmonary disease (COPD), following promising early clinical results from a trial in the Netherlands.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.